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Abstract 
Lame broiler chickens perform poorly in standardised mobility tests and have nociceptive thresholds 
that differ from those of non-lame birds, even when confounding factors such as differences in 
bodyweight are accounted for. This study investigated whether these altered responses could be due to 
pain, by comparing performance in a Group Obstacle test and a Latency to Lie (LTL) test of lame 
(Gait Score (GS) 2.5–4) and non-lame (GS 0–1) broilers administered analgesia or a saline control. 
We used exploratory subcutaneous doses of the Non-Steroidal Anti-Inflammatory Drugs meloxicam 
(5mg/ kg) or carprofen (35mg/kg) or the opioid butorphanol tartrate (4mg/kg). We included 
butorphanol to explore the possibility that NSAID drugs could improve mobility by reducing 
inflammation without necessarily invoking an analgesic effect. Lameness was a significant predictor 
in all analyses. Neither the number of obstacle crossings nor latency to cross an obstacle was 
significantly changed by either NSAID, but LTL was longer in lame birds given carprofen and 
meloxicam than in lame birds given saline. LTL was associated with foot pad dermatitis and 
ameliorated by both NSAIDS. Butorphanol did not affect LTL but appeared soporific in the obstacle 
test, increasing latency to cross and, in non-lame birds, reducing the number of crossings. Combined 
with data from other studies, the results suggest carprofen and meloxicam had some analgesic effect 
on lame birds, lending further support to concerns that lameness compromises broiler welfare. Further 
investigation of opioid treatments and lameness types is needed to disentangle effects on mobility and 
on pain. 
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Introduction 
A report in 2009 by the Farm Animal Welfare Council concluded that insufficient progress was being 
made in addressing the problem of lameness in broiler chicken production (FAWC, 2009). Part of the 
difficulty in reducing lameness probably stems from its variability and multifactorial aetiology 
(Bradshaw et al., 2002) and so far, correlations between lameness and underlying pathology have 
proven to be weak (McNamee et al., 1998; Sandilands et al., 2011; Fernandes et al., 2012). Recent 
work by our group has examined the influence of lameness on tests of mobility and nociceptive 
processing in commercially reared broiler chickens, while also modelling other factors that might 
explain test performance and that are often confounded with lameness (such as body mass, sex and 
signs of pathology). Lame broilers made fewer, later crossings than non-lame broilers in an obstacle 
test and had a shorter Latency to Lie (LTL) in a shallow water bath – i.e. to avoid a mildly aversive 
experience (Caplen et al, 2014). In a related study, lameness was also associated with altered thermal 
nociceptive threshold (Hothersall et al, 2014). Importantly, lameness was the most consistent 
predictor of performance across these tests: other factors explained less variability in results or 
became non-significant when lameness was included in the models. These findings suggest that 
lameness in commercial broilers is not simply synonymous with reduced mobility or activity and may 
include an element of pain or discomfort.  
 
A relationship between lameness and pain would be confirmed if differences between lame and non-
lame birds’ performance on such tests were reversed or attenuated by administration of analgesic 
drugs. There is already some evidence to support this: data from kinematic analysis in lame broilers 
indicated that the NSAIDs carprofen and meloxicam caused objective changes in gait, including 
increased walking velocity (Caplen 2013a). Both drugs were also successful in reversing hyperalgesia 
(indicated by a lower nociceptive threshold) associated with induced hock inflammation (Caplen et 
al., 2013b). Finally, meloxicam elevated nociceptive threshold in lame commercial broilers, though 
this group of birds did not show hyperalgesia before treatment (Hothersall et al., 2014). 
 
We therefore tested the efficacy of carprofen and meloxicam on the Obstacle and LTL tests described 
by Caplen and colleagues (2014). In addition, we included the opioid butorphanol tartrate, which is 
regularly used in the management of both chronic and acute pain in birds (Paul-Murphy, 2008).  
Unlike NSAIDs, opioid drugs act without affecting inflammation so can help to discriminate between 
analgesic effects and improvements to mobility that could occur independently of pain.  
 
Evidence exists for a therapeutic action for each of these drugs in poultry and other bird species, but 
there has been little systematic evaluation of appropriate analgesic doses. Routes of administration 
and timing of post-treatment data collection also vary widely within the existing literature. 
 
Meloxicam: Cole et al (2009) observed that an intramuscular injection of 1.0 mg/kg meloxicam 
improved weight-bearing in Hispaniolan parrots (Amazona ventralis) with experimentally induced 
arthritis. Graphical data presented as part of this study indicated that the most substantial 
improvement occurred 2-6 h post-treatment. Baert & DeBacker (2002, 2003) described 
pharmacokinetic parameters of an intravenous dose of meloxicam at 0.5mg/kg in broiler chickens 
based on doses previously used in other species. They reported an elimination half-life of 3.21 hours, 
but did not include a behavioural assay. Recent work within our group using a higher subcutaneous 
dose of 5 mg/kg revealed objective changes in gait parameters after 3h (Caplen et al., 2013a) and 
altered nociceptive threshold (Caplen et al., 2013b) 6h post-treatment, both in lame broilers. 
 
Carprofen: McGeown et al (1999) observed beneficial effects of carprofen on broiler chicken 
mobility at a dose of 1 mg/kg (subcutaneously). Danbury et al (2000) reported that lame chickens 
offered food dosed with 4mg/kg carprofen selected more drugged feed than did non-lame birds, 
though these findings were not replicated in a recent study (Siegel et al., 2011). In laying hens, 
Hocking et al., (2005) concluded that a minimum of 30 mg/kg was required to attenuate signs of 
experimentally induced pain using an intra-muscular route. Caplen and colleagues (2013a,b) also 
reported beneficial effects on mobility and nociceptive threshold following a subcutaneous dose of 
carprofen at 25mg/kg, and pharmacokinetic data (Hothersall et al., 2012) confirmed that plasma 
concentrations of carprofen were higher at 3-6 h compared with 1h following sub-cutaneous injection 
at 15, 25 or 35 mg/kg. 
 
Butorphanol: Sladky et al (2006) state that doses of 2-4mg/kg butorphanol tartrate are widely used in 
psittacine birds and must be administered every 2-4 hours. Guzman et al (2011) concluded that for a 5 
mg/kg dose in Hispaniolan parrots (Amazona ventralis), maintenance of plasma concentrations 
“consistent with published therapeutic levels” would require dosing every 2 h intravenously or 3 h 
intramuscularly. A sub-cutaneous dose of 0.5mg/kg improved weight-bearing in lame turkeys in the 
30 minutes after injection (Buchwalder & Uber-Eicher, 2005) 2 mg/kg was effective in improving 
mobility in laying hens with keel fractures measured from 30 min post-treatment (Nasr et al., 2012). 
No data detailing appropriate doses or effects of butorphanol are available for broilers but a 
pharmacokinetic study in broilers concluded that intravenous injection of 2mg/kg butorphanol 
resulted in drug levels “above the minimum effective concentration for analgesia in mammals” for 
approximately 2 hours (Singh et al., 2011). Surprisingly, however, subcutaneous butorphanol at 
4mg/kg did not have any significant effect on nociceptive threshold in broilers up to 2 hours after 
administration (Hothersall et al., 2014). 
 
Based on these data and pilot studies, we carried out exploratory studies to examine the effect of two 
NSAIDs (5 mg/kg meloxicam and 35 mg/kg carprofen) and an opioid (4 mg/kg butorphanol tartrate) 
on performance in the Obstacle and LTL tests described in Caplen et al (2014). The aim was to 
determine whether differences in mobility between lame and non-lame birds could be reversed or 
reduced by analgesic treatment. If analgesic drugs were effective in relieving lameness-related pain, it 
was hypothesised that latency to lie and the number of crossings in the obstacle test would be 
increased in lame birds receiving drug treatment. For the NSAIDs, it was expected that activity in the 
obstacle test was most likely to be affected in the latter half of the test, whereas butorphanol was 
expected to act more quickly and might therefore also decrease the latency of lame birds to first cross 
the barrier. 
 
 
Methods 
Birds 
Mixed sex broiler chickens of two commercial strains were acquired from various farms located 
within South West England at 25-35 days of age. On each farm visit we collected approximately equal 
numbers of non-lame (Gait Score 0) and lame (Gait Score 3) birds (hereafter referred to as a flock) 
using the gait scoring criteria of Kestin et al (1992). From most flocks 14 lame and 14 non-lame birds 
were selected. Birds were individually colour marked using stock marker spray and housed in pens 
(3.05 x 1.22 m) on wood shavings at a density not exceeding the legal requirements for housing birds 
undergoing scientific procedures. Animal accommodation was climate-controlled at approximately 
20˚C and maintained on a 16 h light: 8 h dark schedule. Birds had ad libitum access to water and 
commercial feed. 
 
Measurement of bird characteristics 
Birds were tested within the age range of 28 - 46 days.  Age at testing was always balanced across test 
groups within any flock. Immediately pre-testing, birds were weighed and gait scored by two 
experienced observers, as described in Hothersall et al (2014). Hock burn and foot pad dermatitis 
(FPD) were recorded on a scale of 0-4 (Welfare Quality, 2009) and birds were assigned a score based 
on the mean of both legs. Sex was determined at post-mortem, within 3 days of completion of testing, 
at which time hock joints were dissected and any gross pathology (e.g. swelling, excessive fluid, 
angular deformity) recorded. This was combined additively with observations made during gait 
scoring to provide binary scores indicating the presence or absence of pathology (any one or more of: 
infection, injury, bone deformity). 
 
Quantitative measures of mobility 
Each test (LTL or obstacle test) was performed following injection of an analgesic or saline control 
(see below). Birds from within a single flock all received the same analgesic treatment (or saline). 
Gait score remained stable for only a short period following transfer to the research facility (including 
both improvements and substantial decline) so most flocks were only kept for four testing days. The 
narrow time window for testing meant it was not possible to employ a cross-over design or to subject 
all birds within a flock to both tests (though most birds did undergo both tests). Birds of Gait Score 0-
1 were included within the category ‘non-lame’ and bird of Gait Score 2.5-4 were classified as ‘lame’. 
Within these categories, exact gait score was also balanced as far as possible across treatments. Group 
sizes for each treatment are provided in Table 1 and the tests themselves are described in detail within 
Caplen et al (2014). 
 
Obstacle test 
The obstacle test was conducted in the home pen using groups of 12 birds following 1 h food 
withdrawal. Groups contained equal numbers of lame and non-lame birds as far as possible; where 
necessary one or more birds of intermediate gait score were included to maintain group sizes but data 
associated with such individuals were not analysed. A block barrier (10cm high, 21.5 cm wide) 
divided the middle of the pen, creating an obstacle between the feeder and drinker. At the start of the 
test, all birds were placed at the drinker and continuous video footage was then recorded for 5 hours. 
The number of times each bird stepped up onto the obstacle (described as a ‘crossing’) during the test 
and the latency of each bird to first perform a crossing was recorded retrospectively from video 
footage.  
 
Latency to Lie (LTL) test 
Briefly, each bird was removed from the home pen and placed individually into a plastic box 
containing a 4cm depth of tepid water and a base of non-slip rubber matting. Several birds were tested 
simultaneously, in visual but not auditory isolation. The time taken (‘latency’) for the bird to sit (‘lie’) 
was recorded, up to a maximum of 15 minutes, after which the bird was dried and returned to the 
home pen.  
 
Analgesic treatment 
All treatments were administered subcutaneously into the dorsal neck. Control birds for all groups 
received 1.5 mL saline; the meloxicam group received 5 mg/kg of Metacam (5 mg/mL injectable 
solution, Boehringer Ingelheim), and the carprofen group received 35 mg/kg of Rimadyl (50 mg/mL 
injectable solution, Pfizer Animal Health). The butorphanol group received 4 mg/kg of Torbugesic 
(1% W/V injectable solution, Fort Dodge Animal Health). For the NSAID treatments the LTL test 
was performed once at 5 h post-treatment; however, for butorphanol (a faster acting drug) the LTL 
test was performed three times: pre-treatment (hr 0) and then at 1 h and 2 h post-treatment.  For all 
drug treatments the Obstacle test was conducted immediately following treatment until 5 h post-
treatment, and specific intervals were also examined at the analysis stage. Birds receiving saline were 
tested as per the appropriate drug allocated to that flock. Some birds receiving saline for their first test 
(LTL or obstacle test) were also tested using the other test on a different day.  For this second test they 
received either saline or a drug treatment.  
 
Statistical Analysis  
Data were analysed using MLwiN v2.25 (Rasbash et al., 2012) to create random-intercept nested 
models to adjust for non-independence due to clustering within groups. For the LTL and Obstacle 
tests, the random part of the model comprised two levels, bird (level 1) nested within flock (level 2). 
Our quantitative measures (number of obstacle crossings, latency to cross the obstacle, or latency-to-
lie) formed the response variables, as appropriate, and the predictors (covariates) tested included a 
binary score for lameness1 (GS for the carprofen group due to lack of saline control group), age, sex, 
mass, binary scores for the various indicators of pathology and ordinal scores for hock burn and foot 
pad dermatitis. Strain was included as an additional predictor within the carprofen data set as flocks 
for this cohort were of two strains. These potential predictors were entered individually into the model 
and any that were significant ( P <0.05) were entered concurrently; those that became non-significant 
were removed. All other variables were then re-entered sequentially and any additional significant 
variables were retained. Standardised residuals were calculated and plotted to ensure that assumptions 
of normality and homoscedasticity were met. The significance of individual predictors in a model was 
tested using Z-tests, whereby the coefficient was divided by the standard error of the coefficient to 
generate respective Z-values. P-values were calculated as the area of the Normal distribution greater 
than or equal to the Z-value, multiplied by two (two-tailed analysis). Interactions between predictors 
were explored where there was an a priori reason to expect a relationship to exist. The significance of 
1 Gait score was also modelled as an ordinal variable but in all cases the binary grouping was more 
parsimonious and was used in the final models. 
                                                          
an interaction in a model was tested using χ2-tests and the deviance in log-likelihood between models 
with and without the interaction. Where more than one predictor made a significant contribution to the 
model, combinations of predictors were included and the model that explained the greatest amount of 
variance was selected. 
 
Occasionally, a bird’s data were excluded from analysis because during testing it showed signs of 
illness that appeared to interfere with normal behavioural responses to the test. 
 
Ethical considerations 
This study was carried out under Home Office Licence (PPL30/2865) and approved by the University 
of Bristol Ethical Review Group. The Home Office Code of Recommendations for the Housing of 
Poultry was met or exceeded at all times. Birds were euthanised by a pre-2013 approved Schedule 
One method (dislocation of the neck or barbiturate anaesthetic overdose) within three days of final 
data collection. Additional pre-determined humane endpoints used in this study were as follows: (i) 
birds that became excessively lame (> GS 4); (ii) any bird that demonstrated obvious signs of distress 
or sickness. 
 
Results 
Population characteristics  
A summary of the main characteristics (lameness risk factors) of the test samples is provided within 
Table 1. Only lame birds were tested with carprofen as insufficient quantities of non-lame birds of an 
appropriate weight were present within the source flocks. Those that were present were deemed 
unsuitable for inclusion within the study as they were either not morphologically representative of a 
broiler chicken at that age, displaying stunted growth, or appeared to be underweight due to illness. 
No such problems were detected amongst the lame birds.  Intra-individual alterations in gait meant 
that some birds were excluded on certain test days as their GS no longer fitted within our prescribed 
range for lame and non-lame birds. For this reason, sample sizes vary slightly between tests. All data 
are unpaired and no attempt was made to examine relationships between the LTL and Obstacle tests. 
 
Obstacle test 
 
Meloxicam 
Meloxicam had no significant effect on total crossings or initial latency to cross the object, in either 
lame or non-lame birds. 
 
The total numbers of obstacle crossings [raw data, mean ± SD (range)] for the 5 h test period were as 
follows: lame + saline = 3.44 ± 3.79 (0-13); lame + meloxicam = 4.18 ± 2.81 (0-11); non-lame + 
saline = 14.40 ± 10.00 (0-39); non-lame + meloxicam = 14.90 ± 9.37 (0-39). Treatment was not a 
significant predictor of total crossings, nor was its interaction with lameness significant. The best 
model, explaining 49.9% of the variability in crossings, consisted of the predictors lameness ( P 
<0.001) and sex ( P <0.001) (Table 2): lame birds made fewer crossings than non-lame birds and 
male birds made fewer crossings than females. Separate models of the first and last two hours of the 
test produced very similar results.  
 
Latencies to first cross the obstacle (s), mean ± SD (range), were as follows: lame + saline = 8565 ± 
7321 (103-18000); lame + meloxicam = 4313 ± 5670 (9-18000); non-lame + saline = 4178 ± 5861 
(47-18000); non-lame + meloxicam = 2333 ± 4398 (98-18000). Latency was best modelled by the 
predictor lameness ( P = 0.023; Table 2), though the model only explained 3.7% of the variation 
within the data set.   
 
Carprofen  
Carprofen did not affect the number of obstacle crossings made by birds or alter latency to first cross 
the obstacle. The total numbers of obstacle crossings [raw data, mean ± SD (range)] for the total 5 h 
test period were as follows: saline = 3.84 ± 2.41 (0-8); carprofen = 3.00 ± 3.27 (0-6). Total crossings 
was best modelled by mass ( P = <0.001) and GS  ( P = 0.002) (Table 2), which explained 30.4% of 
the variation within the data.      
 
On the basis of pharmacokinetic data suggesting that carprofen may have reached its highest 
concentrations in plasma serum in the later stages of the test (Hothersall et al., 2012) two one-hour 
intervals were also modelled (3-4 h, 4-5 h). In each case, drug was not a significant predictor but mass 
and gait score were. 
 
The mean latency [seconds; mean ±SD (range)] to cross the obstacle for each group was as follows: 
saline = 5460 ± 5210 (119 - 18000); carprofen = 8870 ± 6770 (10 - 18000). No variables were found 
to be significant predictors of latency.  
 
Butorphanol 
Butorphanol had no significant effect on total crossings, but was associated with a reduction in 
crossings within the first two hours of the test in non-lame birds. It was also predicted to increase 
latency to first cross in all birds. 
 
The total numbers of crossings [raw data, mean ± SD (range)] for the 5 h test period were as follows: 
lame + saline = 2.96 ± 2.27 (0-8); lame + butorphanol = 2.48 ± 1.90 (0-8); non-lame + saline = 12.12 
± 6.45 (3-30); non-lame + butorphanol = 10.29 ± 6.42 (1-31). Total crossings was best modelled 
using lameness ( P <0.001) as the only predictor, explaining 50.9% of the variation in crossings. 
There was no significant main effect of treatment, nor any interaction between treatment and 
lameness.  
 
Sub-cutaneous injection of butorphanol was recently found to be relatively fast acting in laying hens 
(Nasr et al., 2012), so we also modelled data from the first 2 h of the test.  The number of crossings, 
mean ± SD, for this interval were as follows: lame + saline = 1.17 ± 1.31 (range: 0-6); lame + 
butorphanol = 0.67 ± 0.84 (range: 0-2); non-lame + saline = 4.88 ± 2.51 (range: 0-9); non-lame + 
butorphanol = 2.50 ± 3.01 (range: 0-13). For the 0-2 h crossings results the best model consisted of 
treatment, lameness, and the interaction between the two variables ( P <0.001) (Table 2, Figure 1). 
This model explained 54.5% of the variation. Thus within the first two hours of the test butorphanol 
decreased activity of non-lame birds such that the number of crossings made did not differ 
significantly between lame and non-lame birds.  
 
Latencies to cross the obstacle [s; (mean ± SD (range)] were as follows: lame + saline = 6097 ± 6834 
(78-18000); lame + butorphanol = 7563 ± 5491 (56-18000); non-lame + saline = 1268 ± 1386 (1-
4173); non-lame + butorphanol = 2556 ± 2772 (8-8040).  
 
Latency was best modelled by lameness ( P <0.001), treatment  ( P = 0.046), mass  ( P = 0.023) and 
hock burn  ( P = 0.022) (Table 2), which together explained 35.7% of variation in latency. Being lame 
and receiving butorphanol increased latency by 5619.0 and 953.8 s respectively. In contrast, mass and 
hock burn decreased latency (by 490.6 s per 1 kg increase in body mass and by 474.6 s per one-unit 
increase in hock burn score). 
 
 
The Latency to Lie (LTL) test 
 
Meloxicam 
Modelling showed that meloxicam increased LTL in lame birds. 
 
LTL results (s), mean ± SD (range), were as follows (raw data): lame + saline = 140.8 ± 186.2 (5-
780); lame + meloxicam = 326.9 ± 332.8 (14-900); non-lame + saline = 844.0 ± 168.8 (245-900); 
non-lame + meloxicam = 826.5 ± 204.0 (214-900). The final model accounted for 69.6% of variation 
in latency to lie and contained an interaction between lameness and treatment ( P = 0.017, Table 3). 
Meloxicam increased LTL in lame but not in non-lame birds (Figure 2). 
 
An additional model containing a significant interaction between FPD and treatment (χ2 = 5.69, p = 
0.034) indicated that LTL reduced with increasing FPD severity in those birds receiving saline 
treatment, while LTL was maintained, regardless of FPD severity, in those that received meloxicam 
(Figure 3). This model accounted for 18.7% of variation in the LTL dataset. 
 
Carprofen 
Carprofen was found to increase LTL across the range of gait scores tested. 
 
LTL results (s), mean ± SD, were as follows (raw data): saline = 83.4 ± 107.6 (range: 0-451); 
carprofen = 193.9 ± 247.6 (range: 0-900). The final model contained the predictors GS ( P = 0.001) 
and treatment  ( P = 0.024, Table 3). Latency to lie decreased as gait score increased, but was higher 
in birds treated with carprofen (Figure 4). The model accounted for 31.9% of the variation in latency 
to lie. 
 
An additional model containing a significant interaction between FPD and treatment (χ2 = 9.631, p = 
0.004) indicated that LTL decreased with increasing FPD severity in those birds receiving saline 
treatment, while LTL increased with increasing FPD severity in those that received carprofen (Figure 
5). This model accounted for 30.3% of variation in the LTL dataset. 
 
 
Butorphanol 
Butorphanol treatment had no significant effect on latency to lie, either 1 or 2 hours after injection. 
 
LTL results (s), mean ± SD, were as follows (raw data): lame + saline = 327.2 ± 287.0 (hr 0), 330.5 ± 
336.9 (hr 1), 309.5 ± 285.9 (hr 2); lame + butorphanol = 338.9 ± 297.9 (hr 0), 311.9 ± 289.7 (hr 1), 
364.5 ± 345.0 (hr 2); non-lame + saline = 867.2 ± 114.9 (hr 0), 833.7 ± 191.7 (hr 1) , 830.7 ± 190.3 
(hr 2); non-lame + butorphanol = 900.0 ± 0.0 (hr 0), 900.0 ± 0.0 (hr 1), 843.6 ± 172.5 (hr 2).  
 The latencies to lie of saline- and drug-treated birds did not differ at Hour 0 (pre-treatment) and no 
significant main effect of treatment, nor any interaction with any other predictor, was found either 1 
or 2 h following administration. The data for all 3 time points were, therefore, combined and modelled 
with test nested within bird. This resulted in model containing the predictors lameness ( P <0.001) 
which increased LTL by 573s, pathology  ( P = 0.003) which increased it by 181s and FPD ( P 
<0.001), where a one-unit increase in FPD score was predicted to decrease LTL by 108s (Table 3). 
This model explained 63.9% of the variance in latency. 
 
Although FPD was a significant negative predictor of LTL, there was no evidence of any interaction 
between FPD and treatment within this data set. 
 
Discussion  
As described in the introduction, information about appropriate drug doses and pharmacokinetic 
parameters was fairly limited. This, and the knowledge that genetic factors can influence differential 
sensitivity to analgesia in the domestic fowl (Hughes, 1990), meant our experiments were necessarily 
exploratory. Nevertheless, the results revealed beneficial effects of carprofen and meloxicam on lame 
birds’ latency to lie (LTL). At the doses used, these drugs did not appear to affect activity within the 
Obstacle test, and no beneficial effect of butorphanol was observed in either test. Our findings are 
consistent with our recent demonstration that carprofen and meloxicam obtunded elevated nociceptive 
threshold in a model of lameness (Caplen et al., 2013). As in the larger, pooled sample reported in 
Caplen et al (2014), lameness was again the most consistent predictor of performance in both the 
Obstacle and LTL tests: lameness (or Gait Score) was significant in every individual model except the 
measure of latency to cross the barrier, for carprofen only.  
 
Within the Obstacle test, meloxicam and carprofen treatment were both ineffective at increasing the 
number of crossings, either overall or when we explored results within specific time intervals. The 
lack of effect on latency was not surprising because bioavailability was anticipated to be highest 
several hours after dosing (Baert & DeBacker, 2002, 2003; Hothersall et al., 2012).  The LTL results 
were more promising, with standing times being longer in lame birds administered either NSAID 5h 
previously. Drug treatment was not expected to increase latency in non-lame broilers but, as most 
birds stood for the entire 15 minute test duration, an improvement in standing performance was 
impossible to rule out. In the meloxicam group, data from the drug-treated non-lame birds did not 
reveal a reduction in obstacle crossing or LTL. This was reassuring, as such a reduction might have 
indicated a soporific effect due to an overdose. These findings add to the existing literature from 
model lameness studies and pharmacokinetic data in parrots (Cole et al., 2009; Molter et al., 2013) 
and our nociceptive threshold data (Caplen et al., 2013; Hothersall et al., 2014) to suggest meloxicam 
and, to some extent, carprofen have some therapeutic effect in lame broilers. 
 
It is worth noting that post-hoc analysis of obvious signs of pathology (hock only) revealed 
unexpectedly large differences in pathology type between some sub-groups. It was not a significant 
predictor in any of our models, but nevertheless, this variability could have confounded results if one 
type of pathology was more susceptible to treatment than the other types. In the meloxicam LTL test, 
for example, around one third of lame birds showed signs of pathology. Of those, 87.5% in the saline 
group were classified as showing signs of ‘deformity’ while 71.3% in the meloxicam group were 
scored positive for ‘infection’ (see Table 1). Lameness due to ‘deformity’ might be less amenable to 
improvement by anti-inflammatory drugs than lameness due to other causes, or might encompass 
more and less painful conditions. Reassuringly, over-representation of a pathology type could not 
explain the similar efficacy of carprofen in the LTL test, where distribution of pathologies was more 
consistent. There was no clear pattern overall and many birds exhibited signs of more than one 
pathology type. We also detected pathology in less than 50% of lame birds in any test group. Thus we 
believe that our classification of pathologies was of limited accuracy (rather than identifying a 
genuine imbalance in our groups) and requires further refinement. The data are included here for 
completeness and to inform future studies where lameness type might be of interest. 
 There was no indication from either test that 4mg/kg butorphanol had any beneficial analgesic effect 
on lameness. In fact, it was associated with a decrease in activity in non-lame birds within the first 
two hours of the obstacle test, and an increase in latency (of over 15 minutes) to first cross the 
obstacle. Previous data on effective analgesic doses for broilers were lacking, and suggestions that 
similar or lower doses would be effective in broilers (Singh et al., 2011) and parrots (Guzman et al., 
2011) for around two hours were based on extrapolation from behavioural data in other studies or 
even species. A 2mg/kg sub-cutaneous dose improved mobility in laying hens with healed keel 
fractures (Nasr et al., 2012) but pilot data at this dose had not appeared effective in our broilers. The 
lack of significant effect of butorphanol on total obstacle crossings across the 5 h data set as a whole 
provides some basic information about the duration of effect: it suggests that non-lame birds 
recovered normal behaviour and even showed some rebound effect during the latter stages of the test.  
 
The positive effects of the NSAIDs on the LTL test - which does not require movement - combined 
with the effects of NSAIDs on broiler nociceptive threshold, may indicate that lameness is causing 
some degree of pain or discomfort that is (partially) alleviated by NSAID administration. However, 
the absence of any beneficial effect of butorphanol in either test makes it difficult to unequivocally 
separate pain from mobility. Intriguingly, our drug treatment findings are the opposite of those 
obtained by Nasr and colleagues in laying hens with healed keel bone fractures. In their studies, 
2mg/kg butorphanol reduced latency to fly down from a perch to access a food reward (Nasr et al., 
2012), whereas neither 5mg/kg meloxicam or 25mg/kg carprofen (all subcutaneously) were effective 
in the same test (Nasr et al., 2014). Previous studies have shown great variability in bioavailability 
and clearance rates of drugs in different avian species (eg Baert & deBacker 2003). Given the intense 
selection for growth rate and comparative immaturity at slaughter in broilers, differences between 
laying hens and broiler strains may also be considerable. 
 
Effects of Foot Pad Dermatitis (FPD) on LTL 
We previously found that broilers with worse FPD sat significantly quicker in water in the LTL 
(Caplen et al., 2014). This finding prompted us to conduct separate analyses to explore the 
relationship between analgesia and FPD in the LTL tests. In all three groups in this study, LTL again 
decreased with increasing severity of FPD. This appeared to be ameliorated by both meloxicam and 
carprofen, though not by butorphanol. However, FPD was only significant in the final (most 
parsimonious) model of LTL for butorphanol. FPD scores were highly variable and were not totally 
balanced across groups so this finding should be interpreted with caution, but may merit further 
systematic evaluation. 
 
Utility of tests 
As per Caplen et al (2014), for each group, the LTL test again explained the highest percentage of 
variance (range 31.9-69.6%), followed by Obstacle crossings (30.4-54.0%), with the lowest 
percentage of variance explained by Latency (3.7-35.7%). This suggests that the factors we modelled 
were able to explain more of the variation in LTL than of the birds’ activity in the Obstacle test. An 
additional advantage of the LTL test is that it is quick and easy to set up. The obstacle test had the 
advantage of being non-invasive but while it was able to detect the relatively large effects of lameness 
or increasing Gait Score on activity, it did not appear to detect any putative influence of drug 
treatment. In this test, the greatest explanatory power was found for the butorphanol group, which was 
probably due in part to the rapid decrease in activity (and thus overall variability) caused by the drug. 
It seems likely that the LTL was more sensitive because the response was less ‘voluntary’, in that 
birds stood to avoid a mildly aversive stimulus. Consistent with this, butorphanol did not reduce 
latency to lie despite a strong sedative effect in the obstacle test. Weeks et al (2000) found that lame 
birds adapted their behaviour in a way that minimised movement while maintaining overall food 
intake; the single session of the Obstacle test may not have been long enough for lame birds to 
overcome habitual sedentary behaviour, though we expected them to be very motivated to reach the 
food.  
 
The use of commercial, spontaneously lame birds was an important element of this study because they 
are representative of the populations and rearing conditions in which lameness occurs. However, it did 
inevitably compromise experimental control to some degree.  We administered a single drug dose, 
whereas extended use of NSAIDS over several days might have increased any physiological or 
mechanical improvement to lame birds. However, repeated testing would have been subject to error 
from changes in Gait Score, including loss of birds that deteriorated over the testing period. The 
instability of Gait Score – even within our short testing period – is very likely to have reduced our 
ability to detect treatment effects. The aetiology of lameness in our birds could also not be fully 
known, and there was large variability in some parameters. We attempted to record (very obvious) 
signs of pathology or illness; these had little predictive power and were almost all found in the lame 
birds, but a small number of non-lame birds showed signs of pathology or did not, for example, make 
any obstacle crossings. Sandilands et al (2011) previously found that links between gait score and 
pathology in broilers were weak, and it is possible that at least some birds reaching our sample age 
group without becoming lame had some pathologies that were not detected in this study. We included 
measures of pathology opportunistically because we were unable to avoid some heterogeneity in our 
birds, focussing on the hock because early indications suggested this was the most common site of 
pathology in our samples. Our assessment appears to have been too blunt to accurately reflect 
lameness aetiology. If possible, application of the behavioural tests to groups of birds with known and 
consistent lameness aetiology would be informative. 
Conclusions. 
The Obstacle and LTL tests are minimally invasive behavioural assays that discriminate well between 
lame and non-lame birds. This study found promising evidence that either 5mg/kg of meloxicam or 35 
mg/kg carprofen was able to partially ameliorate reduced latency to lie in spontaneously lame 
commercial broiler chickens. No evidence of a beneficial effect of 4 mg/kg butorphanol was found, 
and it was unclear how effectively we were able to identify heterogeneous causes of lameness that 
could have influenced the efficacy of drug treatments. As a result we were unable to unequivocally 
exclude a simply anti-inflammatory action by the NSAIDS.  In conjunction with findings that these 
NSAID drugs alter nociceptive threshold, the results suggest that meloxicam and carprofen may have 
an analgesic effect on lame broilers, but further testing of opioid analgesics is needed to differentiate 
between the influences of mobility and pain on LTL. Ideally, the tests outlined here should also be 
replicated in birds of homogeneous lameness type and severity, though this may be difficult to 
achieve within a commercial sample. 
 
Animal welfare implications 
Altered mobility (latency to lie) in commercially reared lame birds was attenuated by NSAID 
analgesics, adding to a growing body of evidence that such lameness involves an element of pain or 
discomfort. 
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Tables 
Table 1: Summary of the characteristics, including post-mortem pathology, of broilers used for the 
Obstacle and LTL tests: (a) Meloxicam; (b) Carprofen; (c) Butorphanol  
 
(a)  
Test Characteristic Saline Meloxicam 
Lame Non-lame Lame Non-lame 
Obstacle Test population 
(n) 
18 16 17 15 
Mass1, kg 
 
1.74±0.26 
(1.27-2.27) 
1.34±0.23 
(1.01-1.72) 
1.76±0.26 
(1.12-2.19) 
1.36±0.24  
(0.83-1.715) 
Sex M: n = 11 
F: n = 7 
M: n = 5 
F: n = 11 
M: n = 13 
F: n = 4 
M: n = 6 
F: n = 9 
Hock Burn1,2 0.15±0.23 
(0-0.75) 
0.05±0.14 
(0-0.5) 
0.85±1.05 
(0-3.0) 
0.13±0.28 
(0-1.0) 
Foot Pad 
Dermatitis1,2 
1.47±0.90 
(0-2.5) 
0.91±0.76 
(0-2.0) 
1.32±0.91 
(0-3.0) 
0.60±0.86 
(0-2.25) 
Pathology (%) 
Type4 (%): 
Infection 
Deformity 
Injury 
33.33 
 
83.33 
33.33 
00.00 
6.25 
 
100.00 
00.00 
00.00 
47.06 
 
50.00 
62.50 
00.00 
0 
 
0.0 
0.0 
0.0 
LTL Test population 
(n) 
22 22 19 16 
Mass1, kg 
 
1.86±0.33 
(1.01-2.39) 
1.51±0.28 
(0.99-2.11) 
1.89±0.31 
(1.28-2.39) 
1.40±0.26 
(1.02-1.95) 
Sex M: n = 17 
F: n = 5 
M: n = 8 
F: n = 14 
M: n = 10 
F: n = 9 
M: n = 8 
F: n = 8 
Hock Burn1,2 0.49±0.61 0.06±0.13 0.65±1.02 0.14±0.24 
(0-1.75) (0-0.5) (0-3.0) (0-0.75) 
Foot Pad 
Dermatitis1,2 
1.35±0.91 
(0-2.5) 
0.43±0.60  
(0-1.75) 
1.38±0.90 
(0-3.0) 
1.20±0.90 
(0-2.25) 
Pathology (%) 
Type4 (%): 
Infection 
Deformity 
Injury 
36.36 
 
37.50 
87.50 
0.00 
0.00 
 
0.00 
0.00 
0.00 
36.84 
 
71.43 
42.86 
0.00 
0.00 
 
0.00 
0.00 
0.00 
 
(b)    
Test Characteristic Saline Carprofen 
Lame Non-lame Lame Non-lame 
Obstacle Test population 
(n) 
19 n/a 16 n/a 
Mass1, kg 
 
2.10±0.37 
(1.46-2.76) 
n/a 2.04±0.48 
(1.33-3.04) 
n/a 
Sex M: n = 11 
F: n = 8 
n/a M: n = 13 
F: n = 3 
n/a 
Hock Burn1,2 0.11±0.20 
(0-0.5) 
n/a 0.12±0.21 
(0-1.0) 
n/a 
Foot Pad 
Dermatitis1,2 
0.94±0.93 
(0-2.5) 
n/a 1.21±0.92 
(0-3.0) 
n/a 
Pathology (%) 
Type4 (%): 
Infection* 
Deformity 
Injury 
5.26 
 
 100.00 
0.00 
0.00 
n/a 37.50 
 
50.0 
33.33 
33.33 
n/a 
LTL Test population 
(n) 
16 n/a 16 n/a 
Mass1, kg 
 
1.74±0.42 
(0.97-2.57) 
n/a 1.73±0.34 
(1.18-2.39) 
n/a 
Sex M: n = 11 
F: n = 5 
n/a M: n = 9 
F: n = 7 
n/a 
Hock Burn1,2 0.19±0.19 
(0-0.5) 
n/a 0.20±0.37 
(0-1.0) 
n/a 
Foot Pad 
Dermatitis1,2 
0.69±0.54 
(0-1.5) 
n/a 0.50±0.66 
(0-2.0) 
n/a 
Pathology (%) 
Type4 (%): 
Infection* 
Deformity 
Injury 
43.75 
 
57.14 
42.86 
28.57 
n/a 43.75 
 
57.14 
42.86 
14.29 
n/a 
 
(c) 
Test Characteristic Saline Butorphanol 
Lame Non-lame Lame Non-lame 
Obstacle Test population 
(n) 
24 25  18 15 
Mass1, kg 
 
1.92±0.31 
(1.40-2.40) 
1.62±0.21 
(1.28-2.20) 
2.06±0.29 
(1.50-2.59) 
1.68±0.17 
(1.47-2.12) 
Sex M: n = 21 
F: n = 3 
M: n = 5 
F: n = 20 
M: n = 18 
F: n = 2 
M: n = 2 
F: n = 13 
Hock Burn1,2 0.19±0.28 
(0-0.75) 
0.05±0.18 
(0-0.75) 
0.11±0.20 
(0-0.75) 
0.08±0.18 
(0-0.5) 
Foot Pad 
Dermatitis1,2 
0.80±1.08 
(0-3.0) 
0.64±0.71 
(0-3.0) 
0.83±0.82 
(0-2.5) 
0.37±0.60 
(0-2.0) 
Pathology (%) 
Type4 (%): 
37.50 
 
4.00 
 
38.89 
 
0.00 
 
Infection* 
Deformity 
Injury 
55.56 
77.78 
22.22 
100.00 
0.0 
0.0 
57.14 
57.14 
0.00 
0.00 
0.00 
0.00 
LTL Test population 
(n) 
21 24 17 15 
Mass1, kg 
 
1.98±0.25 
(1.44-2.40) 
1.61±0.23 
(1.12-2.19) 
2.03±0.27 
(1.54-2.40) 
1.74±0.20 
(1.34-2.20) 
Sex M: n = 18 
F: n = 3 
M: n = 5 
F: n = 19 
M: n = 15 
F: n = 2 
M: n = 2 
F: n = 13 
Hock Burn1,2 0.4±0.89 
(0-3.0) 
0.25±0.73 
(0-3.0) 
0.19±0.27 
(0-0.75) 
0.17±0.26 
(0-0.75) 
Foot Pad 
Dermatitis1,2 
0.87±1.08 
(0-3.0) 
0.64±0.73 
(0-3.0) 
0.60±0.87 
(0-2.5) 
0.35±0.43 
(0-1.0) 
Pathology (%) 
Type4 (%): 
Infection 
Deformity 
Injury 
28.57 
 
33.33 
100.00 
16.67 
4.17 
 
100.00 
0.0 
0.0 
47.06 
 
50.00 
62.50 
12.50 
0.00 
 
0.00 
0.00 
0.00 
1 Mean ± SD (range) 
2 Value assigned according to a severity scale of 0-4, where 0 = none, 4 = severe open ulcers (Welfare Quality, 
2009). A score of 3 was the maximum seen within the test population.  
4Of those individuals with an identified pathology the prevalence of each pathological ‘type’ was also 
calculated. The different types were tallied separately; an individual could display more than one so percentages 
may total >100%. 
* Either localised hock joint infection or systemic infection. 
Table 2: Final models of significant predictors for broiler performance in the obstacle test.  
 
Group Measure Predictor Coef SE (Coef) χ2 df z p 
M
el
ox
ic
am
 Total crossings1 
Constant 4.37 0.23   18.77 <0.001 
Lameness 1.91 0.23   8.20 <0.001 
Sex 0.80 0.23   3.46 <0.001 
Latency2 Constant 6.70 0.55   12.20 <0.001 
Lameness 0.92 0.41   2.27 0.023 
 
C
ar
pr
of
en
 Total crossings2 
Constant 1.44 0.27   5.26 <0.001 
M  0 33 0 10   3 40 <0 001 Gait Score -0.29 0.09   -3.15 0.002 
 
B
ut
or
ph
an
ol
 
Total crossings1 Constant 2.38 0.09   27.96 <0.001 
Lameness -1.06 0.12   -8.91 <0.001 
0-2h crossings1 
Constant 2.48 0.08   32.16 <0.001 
Lameness -0.9 0.11   -8.07 <0.001 
Treatment -0.42 0.09   -4.85 <0.001 
Lameness*Treatment   65.72 1  <0.001 
Latency1 
Constant 25.28 6.61   3.82 <0.001 
Lameness 53.83 9.47   5.68 <0.001 
Mass -37.48 16.54   -2.27 0.023 
Hock burn -38.11 17.56   -2.29 0.022 
Treatment 14.63 7.30   2.00 0.046 
1square-root transformed 
2natural log transformed 
Table 3: Final models of significant predictors for broiler latency to lie. 
Treatment Group Predictor Coefficient SE (Coefficient) χ2 df z p 
Meloxicam Constant 844.05 45.27   18.65 <0.001 
Lameness -733.66 64.78   -11.33 <0.001 
Treatment -17.55 69.77   -0.25 ns 
Lameness*Treatment   5.63 1  0.017 
 
Carprofen1 Constant 7.24 1.43   5.08 <0.001 
Treatment 4.56 2.02   2.26 0.024 
GS -7.83 2.39   -3.28 0.001 
 
Butorphanol Constant 910.13 32.75   27.78 <0.001 
Lameness -573.12 47.07   -12.17 <0.001 
FPD -108.46 26.28   -4.13 <0.001 
Pathology 180.57 60.56   2.98 0.003 
1square-root transformed 
Figures 
 
 
Figure 1: Effect of butorphanol on obstacle crossings. Back-transformed model estimates of the 
number of obstacle crossings (mean ± 95% CI) by lame and non-lame broilers in the two hours after 
treatment (saline or 4mg/kg butorphanol). 
 Figure 2: Effect of meloxicam on latency to lie (LTL). Model estimates for LTL (mean ± 95% CI) in 
lame and non-lame broilers tested 5 hours following treatment (saline or 5mg/kg meloxicam). 
 
  
Figure 3: Model estimates for the relationship between latency to lie (± 95% CI) and foot pad 
dermatitis (FPD) severity in broilers treated with saline or 5 mg/kg meloxicam. 
 
 Figure 4: Effect of carprofen on latency to lie (LTL). Back-transformed model estimates (means ± 
95% CI) of the effect of treatment (saline versus 35 mg/kg carprofen) on LTL in lame broilers 
differing in gait score. 
 
 
 Figure 5: Model estimates for the relationship between latency to lie (± 95% CI) and foot pad 
dermatitis (FPD) severity in broilers treated with saline or 35 mg/kg carprofen. 
 
